Status:
RECRUITING
Preventing Alzheimer's With Cognitive Training
Lead Sponsor:
University of South Florida
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Age-related Cognitive Decline
Alzheimer's Disease and Related Dementias
Eligibility:
All Genders
65+ years
Phase:
PHASE3
Brief Summary
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitiv...
Detailed Description
Preventing Alzheimer's Disease with Cognitive Training: The PACT Trial The primary objective in the R56 phase was to establish the feasibility of the proposed field trial including meeting participan...
Eligibility Criteria
Inclusion
- Be age 65 or older at time of consent
- Have ability to speak and understand English or Spanish
- Report adequate sensorimotor capacity to perform the computer exercises
- Report adequate visual capacity to read from a computer screen at a typical viewing distance
- Show adequate auditory capacity to understand conversational speech
- Show adequate motor capacity to touch a computer screen or control a computer mouse.
- Have no evidence of Mild Cognitive Impairment (MCI) or dementia, as assessed by the Montreal Cognitive Assessment score \>=26.
- Have adequate mental health (no self-reported diagnoses of mental illness that would interfere with ability to comply with study procedures or benefit from intervention)
- Wiling to complete all study activities
- Ability to understand study procedures and comply with them for the length of the study
Exclusion
- Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition
- Previous participation in a cognitive training study
- Self-reported vision, hearing, or motor difficulties that would interfere with the ability to complete the study interventions
- Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic brain injury, brain tumor, or a neurological disorder that affects cognition or would interfere with the ability to benefit from the study intervention (e.g., Parkinson disease, multiple sclerosis), or any other unstable medical conditions that is predisposing to imminent cognitive or functional decline (e.g., congestive heart failure, chronic obstructive pulmonary disorder dependent on oxygen, or undergoing chemotherapy or radiation).
- Self-reported use of medications typically prescribed for dementia such as: Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, aducanumab, Aduhlem.
- Completion of 10 or more hours of a computerized cognitive training program in the last 5 years such as: Lumosity, Posit Science Brain Fitness, InSight, or Brain HQ, Lace, CogMed, CogniFit, Happy Neuron, Elevate, or Dakim
- Severe depressive symptoms (Geriatric Depression Scale score \>=5)
Key Trial Info
Start Date :
February 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
7600 Patients enrolled
Trial Details
Trial ID
NCT03848312
Start Date
February 19 2019
End Date
January 31 2026
Last Update
September 26 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32611
2
University of Florida
Jacksonville, Florida, United States, 32209
3
University of North Florida
Jacksonville, Florida, United States, 32224
4
The Roskamp Institute
Sarasota, Florida, United States, 34243